Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance ; volume:22 ; number:1 ; day:15 ; month:11 ; year:2022 ; pages:1-17 ; date:12.2022
Cancer cell international ; 22, Heft 1 (15.11.2022), 1-17, 12.2022
- Urheber
-
Kanemaru, Ayumi
Shinriki, Satoru
Kai, Mimi
Tsurekawa, Kanae
Ozeki, Kazuya
Uchino, Shota
Suenaga, Naoki
Yonemaru, Kou
Miyake, Shunsuke
Masuda, Takeshi
Kariya, Ryusho
Okada, Seiji
Takeshita, Hisashi
Seki, Yuki
Yano, Hiromu
Komohara, Yoshihiro
Yoshida, Ryoji
Nakayama, Hideki
Li, Jian-Dong
Saito, Hideyuki
Jono, Hirofumi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-022-02781-x
- URN
-
urn:nbn:de:101:1-2023012809063502005727
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kanemaru, Ayumi
- Shinriki, Satoru
- Kai, Mimi
- Tsurekawa, Kanae
- Ozeki, Kazuya
- Uchino, Shota
- Suenaga, Naoki
- Yonemaru, Kou
- Miyake, Shunsuke
- Masuda, Takeshi
- Kariya, Ryusho
- Okada, Seiji
- Takeshita, Hisashi
- Seki, Yuki
- Yano, Hiromu
- Komohara, Yoshihiro
- Yoshida, Ryoji
- Nakayama, Hideki
- Li, Jian-Dong
- Saito, Hideyuki
- Jono, Hirofumi
- SpringerLink (Online service)
Ähnliche Objekte (12)
VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination
CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
HMGA1 drives chemoresistance in esophageal squamous cell carcinoma by suppressing ferroptosis
EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer
The EGFR phosphatase RPTPγ is a redox‐regulated suppressor of promigratory signaling
EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma
EGFR modulates complement activation in head and neck squamous cell carcinoma
USP28: oncogene or tumor suppressor? a unifying paradigm for squamous cell carcinoma
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer
VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination
CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
HMGA1 drives chemoresistance in esophageal squamous cell carcinoma by suppressing ferroptosis
EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer
The EGFR phosphatase RPTPγ is a redox‐regulated suppressor of promigratory signaling
EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma
EGFR modulates complement activation in head and neck squamous cell carcinoma
USP28: oncogene or tumor suppressor? a unifying paradigm for squamous cell carcinoma
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer
VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination
CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
HMGA1 drives chemoresistance in esophageal squamous cell carcinoma by suppressing ferroptosis
EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer
The EGFR phosphatase RPTPγ is a redox‐regulated suppressor of promigratory signaling
EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma
EGFR modulates complement activation in head and neck squamous cell carcinoma
USP28: oncogene or tumor suppressor? a unifying paradigm for squamous cell carcinoma
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed